CCNE1表达水平与卵巢癌术后抗血管生成治疗反应性及预后的关系  

Relationship between CCNE1 expression level and anti-angiogenic treatment responsiveness and prognosis after ovarian cancer surgery

作　　者：付静静[1] 龚姗[1] 冯悦 金海红[1] 李苗[1] 朱东林[1] FU Jingjing;GONG Shan;FENG Yue;JIN Haihong;LI Miao;ZHU Donglin(Department of Nosocomial Infection,Qinhuangdao Municipal First Hospital,Qinhuangdao,Hebei 066000,China)

机构地区：[1]河北省秦皇岛市第一医院院感科,河北秦皇岛066000

出　　处：《检验医学与临床》2024年第19期2860-2865,2870,共7页Laboratory Medicine and Clinic

基　　金：河北省秦皇岛市科学与技术研究发展计划项目(202004A071)。

摘　　要：目的探讨细胞周期蛋白E1(CCNE1)表达水平与卵巢癌术后抗血管生成治疗反应性及预后的关系。方法选取2019年6月至2021年6月该院收治的卵巢癌患者206例为研究对象,采用免疫组织化学染色分析术后(抗血管生成治疗前)CCNE1表达水平,根据组织学评分分为CCNE1高表达组和CCNE1低表达组,观察两组术后抗血管生成治疗反应,治疗2个疗程后比较两组客观缓解率(ORR)。同时随访2年,观察卵巢癌患者预后情况(以出现死亡为预后不佳),采用多因素Logistic回归分析筛选影响卵巢癌患者术后抗血管生成治疗反应性的相关因素,采用Cox回归分析影响卵巢癌患者预后的相关因素。结果治疗2个疗程后,CCNE1高表达组的ORR为65.63%,明显高于CCNE1低表达组的49.30%(P<0.05)。治疗反应患者肿瘤最大径、CA125水平低于无反应患者(P<0.05),CCNE1高表达比例高于无反应患者(P<0.05)。多因素Logistic回归分析结果显示,CCNE1高表达是卵巢癌患者抗血管生成治疗无反应的保护因素(P<0.05),CA125水平升高、肿瘤最大径增大均是卵巢癌患者抗血管生成治疗无反应的危险因素(P<0.05)。随访2年,6例失访(CCNE1高表达组2例,CCNE1低表达组4例),最终纳入200例,其中92例预后良好,108例预后不佳。Kaplan-Meier生存曲线分析显示,CCNE1高表达组的生存率低于CCNE1低表达组(Log-rankχ^(2)=7.554,P=0.006)。预后良好组肿瘤最大径、手术残余病灶最大径均小于预后不佳组(P<0.05),CCNE1高表达比例低于预后不佳组(P<0.05)。多因素Cox回归分析显示,术后残余病灶最大径增大、CCNE1高表达、肿瘤最大径增大均是卵巢癌患者术后抗血管生成治疗预后不佳的独立危险因素(P<0.05)。结论术后CCNE1表达水平是卵巢癌患者术后抗血管生成治疗反应性的影响因素,同时也是卵巢癌患者预后的影响因素。Objective To explore the relationship between cyclin E1(CCNE1)expression level and anti-angiogenic treatment responsiveness and prognosis after ovarian cancer surgery.Methods A total of 206 patients with ovarian cancer admitted and treated in this hospital from June 2019 to June 2021 were selected as the study subjects.The immunohistochemical staining was used to analyze the expression level of CCNE1 after operation(before anti-angiogenesis treatment).The patients were divided into the CCNE1 high expression group and CCNE1 low expression group according to the histological score.The postoperative anti-angiogenesis treatment response in the two groups was observed.The objective response rates(ORR)after 2 courses of treatment were compared between the two groups.At the same time,a 2-year follow-up was conducted to observe the prognosis of ovarian cancer patients(with death as poor prognosis).The multivariate Logistic regression analysis was used to analyze and screen the related factors affecting the postoperative anti-angiogenic treatment response in the patients with ovarian cancer,and the Cox regression was used to analyze the related factors affecting the prognosis of the patients with ovarian cancer.Results After 2 courses of treatment,ORR of the CCNE1 high expression group was 65.63%,which was significantly higher than 49.30%of the CCNE1 low expression group(P<0.05).The tumor maximum diameter and CA125 level in the patients with treatment response were lower than those in the patients with non-response(P<0.05),and the proportion of CCNE1 high expression was higher than that in the patients with non-response(P<0.05).The results of multivariate Logistic regression analysis showed that high expression of CCNE1 was the protective factor for non-response to anti-angiogenic therapy in the patients with ovarian cancer(P<0.05),while the elevated CA125 level and increased tumor maximum diameter were the risk factors for non-response to anti-angiogenic therapy in the patients with ovarian cancer(P<0.05).After 2 years o

关 键 词：细胞周期蛋白E1 卵巢癌 抗血管生成治疗 治疗反应性 预后 

分 类 号：R446.8[医药卫生—诊断学] R737.31[医药卫生—临床医学]